查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
2030 年融合蛋白市場預測：按類型、應用和地區分類的全球分析
市場調查報告書
商品編碼
1383409

2030 年融合蛋白市場預測：按類型、應用和地區分類的全球分析

Fusion Proteins Market Forecasts to 2030 - Global Analysis By Type (Immunoglobulin Fusion Protein, Parathyroid Hormone Fusion Protein, Cytokines Recombinant Fusion Protein and Other Types), By Application and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球融合蛋白市場規模將達到 298 億美元，預計到 2030 年將達到 454 億美元，預測期內年複合成長率為 6.2%。

融合蛋白是透過連接兩個或多個編碼單獨蛋白質的基因而製成的人造蛋白質。這些混合蛋白用於多種應用，包括生物技術和醫學。在生物技術中，融合蛋白用於生產大量用於研究或治療目的的特定蛋白質。它們也可以用作蛋白質精製的分子標籤或作為研究蛋白質相互作用的工具。

根據 Globocan 2020，新報告的癌症病例數為 19,292,789 例，預計到 2040 年將增加到 28,887,940 例。

慢性病增加

隨著內容和分發管道變得越來越數位化，越來越需要保護寶貴的智慧財產權免受駭客攻擊、資料外洩和詐欺的分發等網路威脅。 DRM 解決方案提供強大的加密、存取控制和監控功能，使網路犯罪分子難以破壞或竊取敏感內容。因此，娛樂、出版和軟體開發等行業擴大採用 DRM 技術來保護自家公司資產，確保內容安全並降低因網路攻擊和盜版而造成收益損失的風險。

開發成本高

將融合蛋白療法推向市場所需的研究、開發和臨床試驗需要大量資金。這些成本包括臨床前測試、廣泛的臨床試驗、法規遵循、製造基礎設施等。高開發成本對於中小型生技公司來說尤其困難，並且會限制創新和競爭力。為了克服這些限制，合作研究、官民合作關係和資助計畫對於支持融合蛋白的研究和開發至關重要。此外，具有成本效益的開發策略和高效的臨床試驗設計可以幫助減輕這種經濟負擔，並最終加速這一重要治療領域的成長。

改進藥物傳輸技術

奈米顆粒、脂質體和綴合物等藥物遞送系統的改進為最佳化基於融合蛋白的治療藥物的給藥和療效提供了潛力。這些技術可以提高融合蛋白的穩定性、生物利用度以及向特定細胞和組織的標靶遞送，最大限度地減少脫靶效應，並提高整體治療效果。隨著藥物傳遞創新的不斷進行，融合蛋白療法對於多種疾病狀態將變得更具吸引力，因為它們不僅會擴大其適用性，而且會提高患者的依從性和舒適度，推動市場成長，並促進技術創新。

安全問題和潛在的副作用

與其他生物製藥一樣，融合蛋白也存在副作用和意外後果的風險。確保此類治療方法的安全性至關重要，任何問題都可能導致法規挫折、公眾懷疑和市場不確定性。在臨床試驗期間對候選融合蛋白進行嚴格評估和監測對於降低這些風險至關重要。解決安全問題需要持續監測、藥物警戒和製定風險管理策略。最終，維持良好的效益風險比對於融合蛋白療法的市場接受度和長期成功至關重要。

COVID-19 的影響：

COVID-19 大流行對融合蛋白市場產生了各種影響。雖然臨床試驗和供應鏈暫時中斷，但生物製藥研發的重要性卻凸顯出來。融合蛋白是治療性介入的多功能候選者，因此人們對其在 COVID-19 治療和疫苗開發方面的潛力越來越感興趣。此次疫情加速了生物技術研究，間接惠及融合蛋白部門。然而，對 COVID-19 相關治療的不確定性和關注暫時轉移了其他醫療條件的資源和注意力，影響了融合蛋白市場研發的整體步伐。

免疫球蛋白（Ig）融合部分預計在預測期內是最大的

免疫球蛋白（Ig）融合部分預計將出現良好的成長。這些工程蛋白質將抗體的抗原特異性辨識與另一種感興趣的蛋白質或胜肽結合。 Ig融合蛋白廣泛應用於生物製藥，作為癌症、自體免疫疾病、感染疾病等多種疾病的標靶治療。此外，它也是診斷的重要工具，有助於準確檢測特定的生物標記。 Ig融合蛋白處於個人化醫療的最前沿，提供客製化的治療方案和創新的研究途徑，為融合蛋白市場的成長和開拓做出了重大貢獻。

生物技術產業預計在預測期內年複合成長率最高

預計生物技術產業在預測期內將以最快的年複合成長率成長。基因工程、重組 DNA 技術和蛋白質表現系統的進步使得能夠創造具有改善的治療特性的複雜融合蛋白。生物技術工具和技術有助於精確設計和修飾融合蛋白，以針對特定疾病或途徑。生技公司在這一領域不斷創新，並推動融合蛋白療法的成長。此外，生物技術的進步促進了高效製造、品管和新型藥物傳輸技術的開發，使融合蛋白成為現代生物製藥創新的基石。

佔比最大的地區：

在預測期內，由於北美市場先進的醫療基礎設施、強大的生物技術部門以及重要的研發活動，預計將繼續佔據大部分市場佔有率。尤其是美國和加拿大，處於基於融合蛋白的治療方法的創新和臨床試驗的前沿。這些國家擁有完善的法律規範和支持政策，鼓勵生物製藥的開發和商業化。此外，慢性病盛行率的不斷上升、對個人化醫療的日益重視以及對醫療保健研究的大量投資，都有助於該地區在融合蛋白市場中佔據主導地位。

複合年複合成長率最高的地區：

亞太地區在香料蘭姆酒市場中發揮重要作用，預計在預測期內複合年複合成長率最高。該地區不斷擴大的製藥和生物技術行業以及龐大的患者群體帶來了巨大的商機。亞太地區的研發投資不斷增加，中國和印度等國家成為生物製藥生產中心。此外，慢性病的盛行率正在上升，推動了對創新治療方法（包括融合蛋白）的需求。亞太地區的市場成長潛力、臨床試驗和製造能力使其成為尋求進入該地區不斷擴大的醫療保健市場的全球生物製藥公司的重點關注點。

免費客製化服務

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和年複合成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章 執行摘要

第2章 前言

  • 概述
  • 利害關係人
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章 市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 應用分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章 全球融合蛋白市場：依類型

  • 免疫球蛋白 (Ig) 融合蛋白
  • 副甲狀腺素(PTH) 融合蛋白
  • 細胞激素重組融合蛋白
  • 其他類型

第6章 全球融合蛋白市場：依應用

  • 嵌合蛋白藥物
  • 生物技術
  • 診斷
  • 藥物輸送
  • 其他用途

第7章 全球融合蛋白市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第8章 進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第9章 公司簡介

  • Abnova
  • Roche
  • Chimerigen
  • Peprotech
  • Amgen Science
  • Astellas Pharma
  • Bristol-Myers Squibb
  • ProSpec
  • Viventia
  • Genzyme
  • Ligand Pharmaceuticals
  • Novus
  • Regeneron
  • Origene
  • Absolute Antibody
Product Code: SMRC24258

According to Stratistics MRC, the Global Fusion Proteins Market is accounted for $29.8 billion in 2023 and is expected to reach $45.4 billion by 2030 growing at a CAGR of 6.2% during the forecast period. Fusion proteins are artificial proteins created by joining two or more genes that code for separate proteins. These hybrid proteins serve various purposes, such as in biotechnology and medicine. In biotechnology, fusion proteins are used to produce specific proteins in large quantities for research or therapeutic purposes. They can also be utilized as molecular tags for protein purification or as tools for studying protein interactions.

According to Globocan 2020, there were 19,292,789 new cases of cancer reported, and this number is expected to increase to 28,887,940 by 2040.

Market Dynamics:

Driver:

Increasing prevalence of chronic diseases

With the growing digitization of content and distribution channels, there is a greater need to protect valuable intellectual property from cyber threats such as hacking, data breaches, and unauthorized distribution. DRM solutions offer robust encryption, access controls, and monitoring capabilities, making it harder for cybercriminals to compromise and steal sensitive content. As a result, industries like entertainment, publishing, and software development are increasingly adopting DRM technologies to safeguard their assets, ensuring content security and reducing the risk of revenue loss due to cyber attacks and piracy.

Restraint:

High development Costs

The research, development, and clinical testing required bringing fusion protein therapies to market demand substantial financial investment. These costs encompass preclinical studies, extensive clinical trials, regulatory compliance, and manufacturing infrastructure. High development expenses can be especially challenging for smaller biotech companies, potentially limiting their ability to innovate and compete. To overcome this restraint, collaboration, public-private partnerships, and funding initiatives are essential to support the research and development of fusion proteins. Additionally, cost-effective development strategies and efficient clinical trial design can help alleviate this financial burden, ultimately fostering the growth of this vital therapeutic sector.

Opportunity:

Improving drug delivery technologies

Enhanced drug delivery systems, such as nanoparticles, liposomes, and conjugates, offer the potential to optimize the administration and effectiveness of fusion protein-based therapies. These technologies can improve the stability, bioavailability, and targeted delivery of fusion proteins to specific cells or tissues, minimizing off-target effects and enhancing overall treatment outcomes. As drug delivery innovations continue to evolve, they not only expand the applicability of fusion proteins but also enhance patient compliance and comfort, making fusion protein therapies more attractive for a wide range of medical conditions and thus driving market growth and innovation.

Threat:

Safety concerns and potential side effects

Fusion proteins, like all biopharmaceuticals, can carry risks of adverse reactions or unintended consequences. Ensuring the safety profile of these therapies is crucial, as any issues can lead to regulatory setbacks, public skepticism, and market uncertainty. The rigorous evaluation and monitoring of fusion protein candidates during clinical trials are essential to mitigate these risks. Addressing safety concerns demands continuous research, pharmacovigilance, and the development of risk management strategies. Ultimately, maintaining a favorable benefit-to-risk ratio is imperative for the market acceptance and long-term success of fusion protein therapies.

COVID-19 Impact:

The COVID-19 pandemic has had mixed effects on the Fusion Proteins market. While it momentarily disrupted some clinical trials and supply chains, it also underscored the importance of biopharmaceutical research and development. Fusion proteins, being versatile candidates for therapeutic interventions, have seen increased interest in potential COVID-19 treatments and vaccine development. The pandemic has accelerated research in biotechnology, thereby indirectly benefiting the fusion proteins sector. However, the uncertainties and focus on COVID-19-related therapies temporarily diverted resources and attention from other medical conditions, impacting the overall pace of research and development in the Fusion Proteins market.

The immunoglobulin (Ig) fusion segment is expected to be the largest during the forecast period

The immunoglobulin (Ig) fusion segment is expected to have a lucrative growth. These engineered proteins combine an antibody's antigen-specific recognition with another protein or peptide of interest. They find extensive use in biopharmaceuticals, offering targeted therapies for a variety of diseases, including cancers, autoimmune disorders, and infectious diseases. Additionally, they serve as indispensable tools in diagnostics, facilitating the precise detection of specific biomarkers. Ig Fusion Proteins are at the forefront of personalized medicine, providing tailored treatment options and innovative research avenues, contributing significantly to the growth and development of the Fusion Proteins market.

The biological technology segment is expected to have the highest CAGR during the forecast period

The biological technology segment is anticipated to witness the fastest CAGR growth during the forecast period. Advances in genetic engineering, recombinant DNA technology, and protein expression systems have enabled the creation of complex fusion proteins with enhanced therapeutic properties. Biotechnology tools and techniques facilitate the precise design and modification of fusion proteins to target specific diseases and pathways. Biotech companies are continuously innovating in this field, driving the growth of fusion protein therapies. Moreover, biotechnological advancements contribute to efficient manufacturing, quality control, and the development of novel drug delivery technologies, making fusion proteins a cornerstone of modern biopharmaceutical innovation.

Region with largest share:

During the forecast period, it is expected that the North American market will continue to hold a majority of the market share due to its advanced healthcare infrastructure, robust biotechnology sector, and significant research and development activities. The United States and Canada, in particular, have been at the forefront of innovation and clinical trials for fusion protein-based therapies. These nations have well-established regulatory frameworks and supportive policies that encourage the development and commercialization of biopharmaceuticals. Additionally, the increasing prevalence of chronic diseases, a growing emphasis on personalized medicine, and substantial investment in healthcare research contribute to the region's dominance in the Fusion Proteins market.

Region with highest CAGR:

The Asia Pacific region plays a significant role in the spice rum market and is projected to have the highest CAGR over the forecast period. The region's expanding pharmaceutical and biotechnology industry, coupled with a large patient population, presents significant opportunities. Asia Pacific is witnessing increased investment in research and development, with countries like China and India becoming hubs for biopharmaceutical production. Furthermore, the prevalence of chronic diseases is on the rise, driving the demand for innovative therapies, including fusion proteins. Asia Pacific's potential for market growth, clinical trials, and manufacturing capabilities make it a key focus for global biopharmaceutical companies aiming to tap into the region's expanding healthcare market.

Key players in the market

Some of the key players in Fusion Proteins market include: Abnova, Roche, Chimerigen, Peprotech, Amgen Science, Astellas Pharma, Bristol-Myers Squibb, ProSpec, Viventia, Genzyme, Ligand Pharmaceuticals, Novus, Regeneron, Origene and Absolute Antibody.

Key Developments:

In August 2022, Amgen Inc. and Teneobio Inc. announced a deal in which Amgen would acquire Teneobio, which is a privately owned clinical-stage biotechnology firm focusing on a novel class of biologics known as Human Heavy-Chain Antibodies. Amgen's capabilities to develop advanced medicine in treating patients with severe diseases and commercialize best-in-class products will be strengthened by the acquisition of Teneobio.

In July 2022, Formation Biologics Inc., which is a protein engineering business specializing in biotherapeutics for cancer and fibrotic disorders was acquired by Bristol-Myers Squibb Company. Bristol-Myers Squibb acquired Forbius' TGF-beta program, including the lead experimental option, AVID200, as part of the acquisition. Primarily, Bristol-Myers Squibb intends to focus on AVID200 R&D in cancer detection, with the possibility of broadening its application to other therapeutic areas such as fibrosis.

Types Covered:

  • Immunoglobulin (Ig) Fusion Protein
  • Parathyroid Hormone (PTH) Fusion Protein
  • Cytokines Recombinant Fusion Protein
  • Other Types

Applications Covered:

  • Chimeric Protein Drugs
  • Biological Technology
  • Diagnostics
  • Drug Delivery
  • Other Applications

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Fusion Proteins Market, By Type

  • 5.1 Introduction
  • 5.2 Immunoglobulin (Ig) Fusion Protein
  • 5.3 Parathyroid Hormone (PTH) Fusion Protein
  • 5.4 Cytokines Recombinant Fusion Protein
  • 5.5 Other Types

6 Global Fusion Proteins Market, By Application

  • 6.1 Introduction
  • 6.2 Chimeric Protein Drugs
  • 6.3 Biological Technology
  • 6.4 Diagnostics
  • 6.5 Drug Delivery
  • 6.6 Other Applications

7 Global Fusion Proteins Market, By Geography

  • 7.1 Introduction
  • 7.2 North America
    • 7.2.1 US
    • 7.2.2 Canada
    • 7.2.3 Mexico
  • 7.3 Europe
    • 7.3.1 Germany
    • 7.3.2 UK
    • 7.3.3 Italy
    • 7.3.4 France
    • 7.3.5 Spain
    • 7.3.6 Rest of Europe
  • 7.4 Asia Pacific
    • 7.4.1 Japan
    • 7.4.2 China
    • 7.4.3 India
    • 7.4.4 Australia
    • 7.4.5 New Zealand
    • 7.4.6 South Korea
    • 7.4.7 Rest of Asia Pacific
  • 7.5 South America
    • 7.5.1 Argentina
    • 7.5.2 Brazil
    • 7.5.3 Chile
    • 7.5.4 Rest of South America
  • 7.6 Middle East & Africa
    • 7.6.1 Saudi Arabia
    • 7.6.2 UAE
    • 7.6.3 Qatar
    • 7.6.4 South Africa
    • 7.6.5 Rest of Middle East & Africa

8 Key Developments

  • 8.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 8.2 Acquisitions & Mergers
  • 8.3 New Product Launch
  • 8.4 Expansions
  • 8.5 Other Key Strategies

9 Company Profiling

  • 9.1 Abnova
  • 9.2 Roche
  • 9.3 Chimerigen
  • 9.4 Peprotech
  • 9.5 Amgen Science
  • 9.6 Astellas Pharma
  • 9.7 Bristol-Myers Squibb
  • 9.8 ProSpec
  • 9.9 Viventia
  • 9.10 Genzyme
  • 9.11 Ligand Pharmaceuticals
  • 9.12 Novus
  • 9.13 Regeneron
  • 9.14 Origene
  • 9.15 Absolute Antibody

List of Tables

  • Table 1 Global Fusion Proteins Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Fusion Proteins Market Outlook, By Type (2021-2030) ($MN)
  • Table 3 Global Fusion Proteins Market Outlook, By Immunoglobulin (Ig) Fusion Protein (2021-2030) ($MN)
  • Table 4 Global Fusion Proteins Market Outlook, By Parathyroid Hormone (PTH) Fusion Protein (2021-2030) ($MN)
  • Table 5 Global Fusion Proteins Market Outlook, By Cytokines Recombinant Fusion Protein (2021-2030) ($MN)
  • Table 6 Global Fusion Proteins Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 7 Global Fusion Proteins Market Outlook, By Application (2021-2030) ($MN)
  • Table 8 Global Fusion Proteins Market Outlook, By Chimeric Protein Drugs (2021-2030) ($MN)
  • Table 9 Global Fusion Proteins Market Outlook, By Biological Technology (2021-2030) ($MN)
  • Table 10 Global Fusion Proteins Market Outlook, By Diagnostics (2021-2030) ($MN)
  • Table 11 Global Fusion Proteins Market Outlook, By Drug Delivery (2021-2030) ($MN)
  • Table 12 Global Fusion Proteins Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 13 North America Fusion Proteins Market Outlook, By Country (2021-2030) ($MN)
  • Table 14 North America Fusion Proteins Market Outlook, By Type (2021-2030) ($MN)
  • Table 15 North America Fusion Proteins Market Outlook, By Immunoglobulin (Ig) Fusion Protein (2021-2030) ($MN)
  • Table 16 North America Fusion Proteins Market Outlook, By Parathyroid Hormone (PTH) Fusion Protein (2021-2030) ($MN)
  • Table 17 North America Fusion Proteins Market Outlook, By Cytokines Recombinant Fusion Protein (2021-2030) ($MN)
  • Table 18 North America Fusion Proteins Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 19 North America Fusion Proteins Market Outlook, By Application (2021-2030) ($MN)
  • Table 20 North America Fusion Proteins Market Outlook, By Chimeric Protein Drugs (2021-2030) ($MN)
  • Table 21 North America Fusion Proteins Market Outlook, By Biological Technology (2021-2030) ($MN)
  • Table 22 North America Fusion Proteins Market Outlook, By Diagnostics (2021-2030) ($MN)
  • Table 23 North America Fusion Proteins Market Outlook, By Drug Delivery (2021-2030) ($MN)
  • Table 24 North America Fusion Proteins Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 25 Europe Fusion Proteins Market Outlook, By Country (2021-2030) ($MN)
  • Table 26 Europe Fusion Proteins Market Outlook, By Type (2021-2030) ($MN)
  • Table 27 Europe Fusion Proteins Market Outlook, By Immunoglobulin (Ig) Fusion Protein (2021-2030) ($MN)
  • Table 28 Europe Fusion Proteins Market Outlook, By Parathyroid Hormone (PTH) Fusion Protein (2021-2030) ($MN)
  • Table 29 Europe Fusion Proteins Market Outlook, By Cytokines Recombinant Fusion Protein (2021-2030) ($MN)
  • Table 30 Europe Fusion Proteins Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 31 Europe Fusion Proteins Market Outlook, By Application (2021-2030) ($MN)
  • Table 32 Europe Fusion Proteins Market Outlook, By Chimeric Protein Drugs (2021-2030) ($MN)
  • Table 33 Europe Fusion Proteins Market Outlook, By Biological Technology (2021-2030) ($MN)
  • Table 34 Europe Fusion Proteins Market Outlook, By Diagnostics (2021-2030) ($MN)
  • Table 35 Europe Fusion Proteins Market Outlook, By Drug Delivery (2021-2030) ($MN)
  • Table 36 Europe Fusion Proteins Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 37 Asia Pacific Fusion Proteins Market Outlook, By Country (2021-2030) ($MN)
  • Table 38 Asia Pacific Fusion Proteins Market Outlook, By Type (2021-2030) ($MN)
  • Table 39 Asia Pacific Fusion Proteins Market Outlook, By Immunoglobulin (Ig) Fusion Protein (2021-2030) ($MN)
  • Table 40 Asia Pacific Fusion Proteins Market Outlook, By Parathyroid Hormone (PTH) Fusion Protein (2021-2030) ($MN)
  • Table 41 Asia Pacific Fusion Proteins Market Outlook, By Cytokines Recombinant Fusion Protein (2021-2030) ($MN)
  • Table 42 Asia Pacific Fusion Proteins Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 43 Asia Pacific Fusion Proteins Market Outlook, By Application (2021-2030) ($MN)
  • Table 44 Asia Pacific Fusion Proteins Market Outlook, By Chimeric Protein Drugs (2021-2030) ($MN)
  • Table 45 Asia Pacific Fusion Proteins Market Outlook, By Biological Technology (2021-2030) ($MN)
  • Table 46 Asia Pacific Fusion Proteins Market Outlook, By Diagnostics (2021-2030) ($MN)
  • Table 47 Asia Pacific Fusion Proteins Market Outlook, By Drug Delivery (2021-2030) ($MN)
  • Table 48 Asia Pacific Fusion Proteins Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 49 South America Fusion Proteins Market Outlook, By Country (2021-2030) ($MN)
  • Table 50 South America Fusion Proteins Market Outlook, By Type (2021-2030) ($MN)
  • Table 51 South America Fusion Proteins Market Outlook, By Immunoglobulin (Ig) Fusion Protein (2021-2030) ($MN)
  • Table 52 South America Fusion Proteins Market Outlook, By Parathyroid Hormone (PTH) Fusion Protein (2021-2030) ($MN)
  • Table 53 South America Fusion Proteins Market Outlook, By Cytokines Recombinant Fusion Protein (2021-2030) ($MN)
  • Table 54 South America Fusion Proteins Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 55 South America Fusion Proteins Market Outlook, By Application (2021-2030) ($MN)
  • Table 56 South America Fusion Proteins Market Outlook, By Chimeric Protein Drugs (2021-2030) ($MN)
  • Table 57 South America Fusion Proteins Market Outlook, By Biological Technology (2021-2030) ($MN)
  • Table 58 South America Fusion Proteins Market Outlook, By Diagnostics (2021-2030) ($MN)
  • Table 59 South America Fusion Proteins Market Outlook, By Drug Delivery (2021-2030) ($MN)
  • Table 60 South America Fusion Proteins Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 61 Middle East & Africa Fusion Proteins Market Outlook, By Country (2021-2030) ($MN)
  • Table 62 Middle East & Africa Fusion Proteins Market Outlook, By Type (2021-2030) ($MN)
  • Table 63 Middle East & Africa Fusion Proteins Market Outlook, By Immunoglobulin (Ig) Fusion Protein (2021-2030) ($MN)
  • Table 64 Middle East & Africa Fusion Proteins Market Outlook, By Parathyroid Hormone (PTH) Fusion Protein (2021-2030) ($MN)
  • Table 65 Middle East & Africa Fusion Proteins Market Outlook, By Cytokines Recombinant Fusion Protein (2021-2030) ($MN)
  • Table 66 Middle East & Africa Fusion Proteins Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 67 Middle East & Africa Fusion Proteins Market Outlook, By Application (2021-2030) ($MN)
  • Table 68 Middle East & Africa Fusion Proteins Market Outlook, By Chimeric Protein Drugs (2021-2030) ($MN)
  • Table 69 Middle East & Africa Fusion Proteins Market Outlook, By Biological Technology (2021-2030) ($MN)
  • Table 70 Middle East & Africa Fusion Proteins Market Outlook, By Diagnostics (2021-2030) ($MN)
  • Table 71 Middle East & Africa Fusion Proteins Market Outlook, By Drug Delivery (2021-2030) ($MN)
  • Table 72 Middle East & Africa Fusion Proteins Market Outlook, By Other Applications (2021-2030) ($MN)